Kutatási jelek – Signal Engine

• Gastrointestinal Stromal Tumors Treatment (PDQ®) — Gastrointestinal stromal tumor
• EORTC and Immunocore Announce Enrolment of First Patient onto the Only Active Phase 3 Adjuvant Trial in Uveal Melanoma — Uveal melanoma
• Drug clinical trial landscape of chronic myeloid leukemia: achieving the endpoint or continuing the journey? — Chronic myeloid leukemia
• Prostate cancer: Three drug trials to watch — Prostate cancer
• FDA approves New Therapy Aimed at a New Target in Esophageal Cancer at the GE Junction — Esophageal cancer
• Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024) — Diffuse large B-cell lymphoma
• Anal Squamous Cell Carcinoma: From Standard Treatment to Personalized Therapy — Anal squamous cell carcinoma
• Translational studies in the GEMMK trial: Optimising immunotherapy in leiomyosarcoma and undifferentiated pleomorphic sarcoma - SFA — Leiomyosarcoma
• Children’s Hospital of Philadelphia Researchers Reveal New Hope for Chemotherapy-Resistant Neuroblastoma Patients — Neuroblastoma
• Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice — Hepatocellular carcinoma
• Hepatocellular Carcinoma — Hepatocellular carcinoma
• Malignant Mesothelioma Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf — Malignant pleural mesothelioma
• Proton Therapy for Squamous Cell Carcinoma — Melanoma
• A Major Milestone in Glioblastoma Research — Glioblastoma
• Breast Cancer — Breast cancer
• Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma — Lymphoma
• Clinical Trial Trends: Non-small Cell Lung Cancer (NSCLC) — NSCLC
• Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis — Myelofibrosis
• Sequencing Considerations in the Third-Line Treatment of Metastatic Colorectal Cancer — Colorectal cancer
• Response Time and BRAF Status Factor Into IO Selection for Melanoma — Melanoma